SECTION 9.3: EXPANDED ACCESS / COMPASSIONATE USE / NAMED PATIENT SUPPLY PROGRAMMES FOR UNLICENSED MEDICINES – GUIDANCE NOTES
![Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone | The British Journal of Psychiatry | Cambridge Core Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone | The British Journal of Psychiatry | Cambridge Core](https://static.cambridge.org/content/id/urn%3Acambridge.org%3Aid%3Aarticle%3AS0007125000049898/resource/name/firstPage-S0007125000049898a.jpg)
Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone | The British Journal of Psychiatry | Cambridge Core
![Initiating Early Access Programs: 5 Things to Consider :: executive insight | healthcare consultants Initiating Early Access Programs: 5 Things to Consider :: executive insight | healthcare consultants](https://www.executiveinsight.ch/application/files/thumbnails/image_sm/5715/2104/1179/initiatingearly_img1.png)